CAR T-Cell Therapy | Clinical

Liso-Cel Efficacy Not Impacted by Prior CD19 Exposure in LBCL

April 25, 2021

In an interview with Targeted Oncology, Scott R. Solomon, MD, a medical oncologist with the Blood and Marrow Transplant Program, Leukemia and Cellular Immunotherapy Program at the Northside Hospital Cancer Institute, discussed the efficacy of liso-cel in large B-cell lymphoma patients with prior anti-CD19 exposure and future research.

Lenzilumab Plus Axi-Cel Achieves Responses in 100% of Patients With DLBCL With Limited Toxicity in Small Study

April 23, 2021

When given at the recommended phase 2 dose, lenzilumab in combination with taxicabtagene ciloleucel, induced a 100% objective response rate while showing no severe cytokine release syndrome cases or severe neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL

April 12, 2021

Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.

Further Promise for CAR T-cell Therapy Use in R/R MCL Observed with Liso-Cel

March 24, 2021

In an interview with Targeted Oncology, Maria Lia Palomba, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center, discussed the efficacy and safety of liso-cel in patients with R/R MCL as observed in the phase 1 TRANSCEND NHL 001 study.

Axi-cel Shows Better Outcomes When Given After Corticosteroids in R/R LBCL

March 24, 2021

Administering corticosteroids prior to chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel in adult patients with relapsed or refractory large B-cell lymphoma may positively impact the benefit/risk profile of axi-cel treatment.

Exploring the Potential of PSCA-Targeted CAR T-Cell Therapy to Treat mCRPC

March 23, 2021

Tanya B. Dorff, MD, a medical oncologist at the City of Hope Cancer Center, discusses the reasoning behind using PSCA-targeted chimeric antigen receptor T-cell therapy and the design of this early study in an interview with Targeted Oncology.